Fulcrum Therapeutics, Inc. (FULC)

3.735 -0.05 (-1.32%) USD  |  NASDAQ  |  Sep 25, 16:00
3.735 0.00 (0.00%) After-Hours: 18:44
More

Fulcrum Therapeutics Research and Development Expense (Annual) : 54.71M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for FULC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2017. Start Trial.
Date Value
December 31, 2025 54.71M
December 31, 2024 61.79M
December 31, 2023 71.80M
December 31, 2022 74.37M
December 31, 2021 67.19M
Date Value
December 31, 2020 56.66M
December 31, 2019 43.43M
December 31, 2018 25.18M
December 31, 2017 18.49M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 5.055M
CNBX Pharmaceuticals, Inc. 0.00
GB Sciences, Inc. --
Arvinas, Inc. 282.90M
Definium Therapeutics, Inc. 117.66M